FLOX in Combination With Cetuximab in First-line Treatment of Colorectal Cancer
Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
The main objective of this trial is to explore the effect of combining an established
chemotherapy regimen (FLOX), based on 5-fluorouracil, folinic acid, and oxaliplatin
(Eloxatin®), with the EGF receptor antibody cetuximab (Erbitux®) in first-line treatment of
metastatic colorectal cancer. The trial will investigate two regimens of FLOX plus cetuximab,
in which FLOX is given continuously or intermittently, compared to standard FLOX without
cetuximab.